Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

ClinicalTrials.gov ID: NCT02682511

Public ClinicalTrials.gov record NCT02682511. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary arterial hypertension (SSc-PAH).

Study identification

NCT ID: NCT02682511
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Cumberland Pharmaceuticals; Industry
Enrollment: 34 participants

Conditions and interventions

Conditions

Interventions

Oral Ifetroban Drug
Oral Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2017 (Actual)
Primary completion: Mar 2026 (Actual)
Completion: Sep 2026 (Estimated)
Last update posted: Sep 2, 2026

2017 – 2026

United States locations

U.S. sites: 10
U.S. states: 10
U.S. cities: 10

Facility	City	State	ZIP	Site status
The Universtity of Arizona Arthrtis Center	Tucson	Arizona	85724	—
UCLA	Los Angeles	California	90095-1670	—
Cleveland Clinic - Florida	Weston	Florida	33331	—
Johns Hopkins University	Baltimore	Maryland	21224	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
University of Nebraska Medical Center	Omaha	Nebraska	68198	—
Hospital for Special Surgery	New York	New York	10021	—
Thomas Jefferson University	Philadelphia	Pennsylvania	19107	—
Medical University of South Carolina	Charleston	South Carolina	29403	—
Baylor Research Institute	Dallas	Texas	75204-651	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02682511, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 2, 2026 · Synced Oct 18, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02682511 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →